RecruitingNCT05934149
Lupus Landmark Study: A Prospective Registry and Biorepository
Lupus Nexus Landmark Study: A Prospective Registry and Biorepository
Sponsor
Lupus Research Alliance
Enrollment
3,500 participants
Start Date
Jun 28, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN).
Eligibility
Min Age: 18 YearsMax Age: 110 Years
Inclusion Criteria4
- Able to understand and comply with study procedures and voluntarily sign a written informed consent document
- Age 18 years or older at the time of enrollment
- Fulfill criteria for SLE based on one or more of the following classifications systems:
- Systemic Lupus Erythematosus International Collaborating Clinic (SLICC) 2012 criteria; European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 criteria; 1997 revised ACR criteria; or Lupus is present per clinical assessment.
Exclusion Criteria3
- Not able to obtain consent
- Not able to meet protocol visit requirements
- Pregnant at the time of enrollment
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(25)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05934149
Related Trials
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
NCT055671981 location
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT0692554214 locations
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
NCT0761121415 locations
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
NCT068399761 location
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT0717528564 locations